Abstract 1476P
Background
Nutritional status is strongly related to the prognosis of mGOJ/GC pts. ICI improved the overall survival (OS) in heavily pre-treated mGOJ/GC pts. The aim of this retrospective study was to investigate the potential prognostic role of nutritional markers in ICI-treated mGOJ/GC pts.
Methods
Twelve serum and anthropometric nutritional markers derived from blood and CT scans [weight, body mass Index (BMI), sagittal and waist diameter, waist to hip ratio (WHR), albumin, glucose, lymphocytes, albumin/globulin ratio (AGR), total serum proteins (PRO), Onodera’s prognostic nutritional index] were retrospectively analyzed at baseline. All variables were categorized according to the MaxStat statistics and analyzed for their prognostic value with univariate (UVA) and multivariate (MVA) cox regression analyses.
Results
From June 2014 to December 2018, 57 mGOJ/GC pts (14 females, 43 males) (median (m) age 63 years) received ICI as second-line therapy (pembrolizumab n=26, nivolumab n=16, avelumab n=15). The mfollow-up was 27 months (mo) (4 to 53 mo). mOS was 10.8 mo (0.2 to 52.2 mo). PRO and WHR were independent predictors for OS in the MVA (hazard ratio (HR) 0.98, p 0.01 and HR 1.31, p 0.03, respectively) and used to build the NUTRICI. Pts with both PRO >60 g/l and WHR >1 had a mOS of 36 mo, vs. 12 mo of pts with one unfavourable factor (either PRO <60 g/l or WHR<1), vs. 4 mo of pts with both unfavorable factors (p 0.0006). Taking as reference pts with both favorable factors, HR was 4.16 and 10.08 for pts with one and two unfavourable factors, respectively.
Conclusions
NUTRICI, combining PRO and WHR, is the first nutritional index with a significant prognostic value in mOGJ/GC pts receiving second-line ICIs. A prospective validation is currently under way.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.